Search Results - "Lovasz, B. D."

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease by Kiss, L. S., Szamosi, T., Molnar, T., Miheller, P., Lakatos, L., Vincze, A., Palatka, K., Barta, Z., Gasztonyi, B., Salamon, A., Horvath, G., Tóth, G. T., Farkas, K., Banai, J., Tulassay, Z., Nagy, F., Szenes, M., Veres, G., Lovasz, B. D., Vegh, Z., Golovics, P. A., Szathmari, M., Papp, M., Lakatos, P. L.

“…Aliment Pharmacol Ther 2011; 34: 911–922 Summary Background  Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven…”
Get full text

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease: Adalimumab predictors in Crohn’s disease by Kiss, L. S., Szamosi, T., Molnar, T., Miheller, P., Lakatos, L., Vincze, A., Palatka, K., Barta, Z., Gasztonyi, B., Salamon, A., Horvath, G., Tóth, G. T., Farkas, K., Banai, J., Tulassay, Z., Nagy, F., Szenes, M., Veres, G., Lovasz, B. D., Vegh, Z., Golovics, P. A., Szathmari, M., Papp, M., Lakatos, P. L.

Get full text